The Lundquist Institute for Biomedical Innovation has announced that the Bill & Melinda Gates Foundation has awarded a 2-year grant of $471,858 to principal investigator Frans Walther for further development of an aerosolized synthetic lung surfactant for the treatment of respiratory distress syndrome (RDS) in newborn babies. In March 2021, the institute announced … [Read more...] about Gates Foundation provides grant for development of aerosolized surfactant for the treatment of RDS in newborns
News
FDA allows additional MS patients in intranasal Foralumab expanded access program
Tiziana Life Sciences said that the FDA has issued a Study May Proceed letter allowing Brigham and Women’s Hospital (BWH) to treat an additional eight patients with secondary progressive multiple sclerosis (SPMS) with Tiziana's intranasal Foralumab under an Intermediate-Size Patient Population Expanded Access IND. The agency evaluated data from treatment of two … [Read more...] about FDA allows additional MS patients in intranasal Foralumab expanded access program
Respira initiates Phase 2b trial of RT234 inhaled vardenafil for PAH
Respira Therapeutics has announced the initiation of a Phase 2b trial of its RT234 dry powder vardenafil in patients with pulmonary arterial hypertension (PAH). The open label study will include two cohorts, with the first receiving a single 0.5 mg dose of RT234 via the Axial Oscillating Sphere inhaler and the second getting a 1 mg dose (2 x 0.5 mg). United … [Read more...] about Respira initiates Phase 2b trial of RT234 inhaled vardenafil for PAH
Lonza joins IPAC-RS
CDMO Lonza has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), the company said. In the announcement of its IPAC-RS membership, Lonza specifically noted its planned participation in discussions related to particle engineering, inhaler testing, devices, and packaging. In July 2020, Lonza announced that it had … [Read more...] about Lonza joins IPAC-RS
Phase 2b challenge study of intranasal PHAD for the prevention of H3N2 flu fails to meet primary endpoint
Revelation Biosciences has announced that a Phase 2b viral challenge study of its REVTx-99a intranasal phosphorylated hexaacylated disaccharide (PHAD) for the prevention of H3N2 influenza in healthy volunteers failed to meet its primary endpoint. The study, which enrolled 30 subjects aged 18 to 55, failed to demonstrate a statistically significant difference in viral … [Read more...] about Phase 2b challenge study of intranasal PHAD for the prevention of H3N2 flu fails to meet primary endpoint
Koura opens HFA 152a production facility
Koura has officially opened a new facility for the production of HFA 152a in Runcorn, UK, the company announced. According to Koura, the propellant produced at the facility, which will be marketed as "Zephex 152a," will be available at commercial scale within a few months. In December 2019, Italian pharma company Chiesi said that it had signed an agreement with … [Read more...] about Koura opens HFA 152a production facility
Proveris Scientific launches Kinaero Cx collection system for automated MDI testing
Proveris Scientific has announced the launch of a new collection system called Kinaero Cx that is designed for improved sample collection consistency during MDI testing. The new system, which includes the company's Vereo automated actuator technology, controls parameters for inhaler shaking and actuation, shake-to-fire timing, and flow rate and can be used for both … [Read more...] about Proveris Scientific launches Kinaero Cx collection system for automated MDI testing
Sapigen Biologix gets funding from TDB for development of intranasal COVID-19 vaccine
The Indian Ministry of Science & Technology's Technology Development Board (TDB) has signed a development and commercialization agreement with Hyderabad-based Sapigen Biologix, committing ₹100 crores to development of a novel intranasal vaccine against COVID-19 and a vaccine against malaria, the ministry said. The ministry said that the TDB funding will cover … [Read more...] about Sapigen Biologix gets funding from TDB for development of intranasal COVID-19 vaccine
FDA clears IND for Blue Lake intranasal RSV vaccine
CyanVac subsidiary Blue Lake Biotechnology is planning a Phase 1 trial of its BLB-201 intranasal vaccine against respiratory syncytial virus (RSV) after receiving FDA clearance for its IND, CyanVac said. The Phase 1 trial will evaluate BLB-201 in two different cohorts, one aged 18-59 and the other aged 60-75. According to the company, preclinical studies of BLB-201 in … [Read more...] about FDA clears IND for Blue Lake intranasal RSV vaccine
Harm Reduction Therapeutics gets additional $11 million for development of naloxone nasal spray
OxyContin maker Purdue Pharma will provide an additional $11 million to non-profit Harm Reduction Therapeutics (HRT) for continued development of HRT's HRT001 naloxone nasal spray for the reversal of opioid overdose. The additional funding was approved by the court overseeing Purdue's bankruptcy. Purdue began funding HRT in 2018, and in 2020, Purdue announced that it … [Read more...] about Harm Reduction Therapeutics gets additional $11 million for development of naloxone nasal spray